122 related articles for article (PubMed ID: 26505792)
1. 3-Deazaneplanocin A suppresses aggressive phenotype-related gene expression in an oral squamous cell carcinoma cell line.
Hatta M; Naganuma K; Kato K; Yamazaki J
Biochem Biophys Res Commun; 2015 Dec 4-11; 468(1-2):269-73. PubMed ID: 26505792
[TBL] [Abstract][Full Text] [Related]
2. Epigenetic alterations of the keratin 13 gene in oral squamous cell carcinoma.
Naganuma K; Hatta M; Ikebe T; Yamazaki J
BMC Cancer; 2014 Dec; 14():988. PubMed ID: 25527207
[TBL] [Abstract][Full Text] [Related]
3. Epigenetic therapy with 3-deazaneplanocin A, an inhibitor of the histone methyltransferase EZH2, inhibits growth of non-small cell lung cancer cells.
Kikuchi J; Takashina T; Kinoshita I; Kikuchi E; Shimizu Y; Sakakibara-Konishi J; Oizumi S; Marquez VE; Nishimura M; Dosaka-Akita H
Lung Cancer; 2012 Nov; 78(2):138-43. PubMed ID: 22925699
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic Modifications with DZNep, NaBu and SAHA in Luminal and Mesenchymal-like Breast Cancer Subtype Cells.
Dagdemir A; Judes G; Lebert A; Echegut M; Karsli-Ceppioglu S; Rifaï K; Daures M; Ngollo M; Dubois L; Penault-Llorca F; Bignon YJ; Bernard-Gallon D
Cancer Genomics Proteomics; 2016; 13(4):291-303. PubMed ID: 27365379
[TBL] [Abstract][Full Text] [Related]
5. Transcutaneous carbon dioxide suppresses epithelial-mesenchymal transition in oral squamous cell carcinoma.
Iwata E; Hasegawa T; Takeda D; Ueha T; Kawamoto T; Akisue T; Sakai Y; Komori T
Int J Oncol; 2016 Apr; 48(4):1493-8. PubMed ID: 26846904
[TBL] [Abstract][Full Text] [Related]
6. Inhibition of S-Adenosylmethionine-Dependent Methyltransferase Attenuates TGFβ1-Induced EMT and Metastasis in Pancreatic Cancer: Putative Roles of miR-663a and miR-4787-5p.
Mody HR; Hung SW; AlSaggar M; Griffin J; Govindarajan R
Mol Cancer Res; 2016 Nov; 14(11):1124-1135. PubMed ID: 27624777
[TBL] [Abstract][Full Text] [Related]
7. TP53 genomic status regulates sensitivity of gastric cancer cells to the histone methylation inhibitor 3-deazaneplanocin A (DZNep).
Cheng LL; Itahana Y; Lei ZD; Chia NY; Wu Y; Yu Y; Zhang SL; Thike AA; Pandey A; Rozen S; Voorhoeve PM; Yu Q; Tan PH; Bay BH; Itahana K; Tan P
Clin Cancer Res; 2012 Aug; 18(15):4201-12. PubMed ID: 22675170
[TBL] [Abstract][Full Text] [Related]
8. Role of EZH2 in oral squamous cell carcinoma carcinogenesis.
Zhao L; Yu Y; Wu J; Bai J; Zhao Y; Li C; Sun W; Wang X
Gene; 2014 Mar; 537(2):197-202. PubMed ID: 24424512
[TBL] [Abstract][Full Text] [Related]
9. DZNep, inhibitor of S-adenosylhomocysteine hydrolase, down-regulates expression of SETDB1 H3K9me3 HMTase in human lung cancer cells.
Lee JK; Kim KC
Biochem Biophys Res Commun; 2013 Sep; 438(4):647-52. PubMed ID: 23933322
[TBL] [Abstract][Full Text] [Related]
10. Superior efficacy of a combined epigenetic therapy against human mantle cell lymphoma cells.
Fiskus W; Rao R; Balusu R; Ganguly S; Tao J; Sotomayor E; Mudunuru U; Smith JE; Hembruff SL; Atadja P; Marquez VE; Bhalla K
Clin Cancer Res; 2012 Nov; 18(22):6227-38. PubMed ID: 22932665
[TBL] [Abstract][Full Text] [Related]
11. Genistein nanoformulation promotes selective apoptosis in oral squamous cell carcinoma through repression of 3PK-EZH2 signalling pathway.
Dev A; Sardoiwala MN; Kushwaha AC; Karmakar S; Choudhury SR
Phytomedicine; 2021 Jan; 80():153386. PubMed ID: 33113500
[TBL] [Abstract][Full Text] [Related]
12. Dysregulation of the repressive H3K27 trimethylation mark in head and neck squamous cell carcinoma contributes to dysregulated squamous differentiation.
Gannon OM; Merida de Long L; Endo-Munoz L; Hazar-Rethinam M; Saunders NA
Clin Cancer Res; 2013 Jan; 19(2):428-41. PubMed ID: 23186778
[TBL] [Abstract][Full Text] [Related]
13. Establishment of 5-fluorouracil-resistant oral squamous cell carcinoma cell lines with epithelial to mesenchymal transition changes.
Harada K; Ferdous T; Ueyama Y
Int J Oncol; 2014 Apr; 44(4):1302-8. PubMed ID: 24452635
[TBL] [Abstract][Full Text] [Related]
14. Eribulin sensitizes oral squamous cell carcinoma cells to cetuximab via induction of mesenchymal-to-epithelial transition.
Kitahara H; Hirai M; Kato K; Bou-Gharios G; Nakamura H; Kawashiri S
Oncol Rep; 2016 Dec; 36(6):3139-3144. PubMed ID: 27779690
[TBL] [Abstract][Full Text] [Related]
15. The Effect of
Özel M; Kilic E; Baskol M; Akalın H; Baskol G
Cell Reprogram; 2021 Apr; 23(2):139-148. PubMed ID: 33861639
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A inhibits the growth of cholangiocarcinoma cells.
Nakagawa S; Sakamoto Y; Okabe H; Hayashi H; Hashimoto D; Yokoyama N; Tokunaga R; Sakamoto K; Kuroki H; Mima K; Beppu T; Baba H
Oncol Rep; 2014 Feb; 31(2):983-8. PubMed ID: 24337160
[TBL] [Abstract][Full Text] [Related]
17. Curcumin Inhibits Invasiveness and Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Through Reducing Matrix Metalloproteinase 2, 9 and Modulating p53-E-Cadherin Pathway.
Lee AY; Fan CC; Chen YA; Cheng CW; Sung YJ; Hsu CP; Kao TY
Integr Cancer Ther; 2015 Sep; 14(5):484-90. PubMed ID: 26036622
[TBL] [Abstract][Full Text] [Related]
18. Loss of GDF10/BMP3b as a prognostic marker collaborates with TGFBR3 to enhance chemotherapy resistance and epithelial-mesenchymal transition in oral squamous cell carcinoma.
Cheng CW; Hsiao JR; Fan CC; Lo YK; Tzen CY; Wu LW; Fang WY; Cheng AJ; Chen CH; Chang IS; Jiang SS; Chang JY; Lee AY
Mol Carcinog; 2016 May; 55(5):499-513. PubMed ID: 25728212
[TBL] [Abstract][Full Text] [Related]
19. Morphological Changes Induced by TKS4 Deficiency Can Be Reversed by EZH2 Inhibition in Colorectal Carcinoma Cells.
Jacksi M; Schad E; Tantos A
Biomolecules; 2024 Apr; 14(4):. PubMed ID: 38672463
[TBL] [Abstract][Full Text] [Related]
20. Aberrant expression of EZH2 is associated with pathological findings and P53 alteration.
Shiogama S; Yoshiba S; Soga D; Motohashi H; Shintani S
Anticancer Res; 2013 Oct; 33(10):4309-17. PubMed ID: 24122997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
